Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14182483 | 0.83 | MAP4K4 (0.39) | MAP4K4TRPV3EIF2AK4GAA | |
| SCHEMBL4850781 | 0.80 | MAP4K4 (0.37) | MAP4K4TRPV3EIF2AK4GAAPIM1 | |
| SCHEMBL12019711 | 0.78 | ALDH1A1 (0.43) | MAP4K4RXFP1MEN1KMT2AGAA | |
| SCHEMBL4858910 | 0.78 | GAA (0.36) | MAP4K4TRPV3EIF2AK4KMT2AGAA | |
| SCHEMBL14213049 | 0.77 | MAP4K4 (0.34) | MAP4K4TRPV3RXFP1EIF2AK4PIM1 | |
| SCHEMBL14627273 | 0.75 | MAP4K4 (0.45) | MAP4K4TRPV3RXFP1EIF2AK4MEN1 | |
| SCHEMBL14213173 | 0.72 | ALDH1A1 (0.38) | GAA | |
| SCHEMBL12019703 | 0.72 | ALDH1A1 (0.38) | GAA | |
| SCHEMBL4859173 | 0.72 | MAP4K4 (0.35) | MAP4K4TRPV3EIF2AK4ACACB | |
| SCHEMBL15898852 | 0.68 | MAP4K4 (0.39) | MAP4K4TRPV3RXFP1EIF2AK4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371746-B2 | 1,2,4-Thiadiazole compounds and pests controlling composition containing the same | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20070004722-A1 | 1,2,4-Thiadazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004722-A1 | 1,2,4-Thiadazole compounds and use thereof | CYP4F3, CYP4B1, CYP4X1 | MAP4K4 1265/4885TRPV3 1922/4885RXFP1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.